Company intelligence / Profile preview

Ainostics

Manchester, United Kingdom

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Ainostics has developed AI-driven tools and analytics platforms supporting earlier clinical diagnosis and trajectory mapping for neurological diseases, focusing on real-world clinical validation, with ongoing work to achieve UK, US, and EU regulatory approvals and early adoption for neurological disorders such as dementia and multiple sclerosis. There are no therapeutics or traditional drug trials; their offering is an advanced clinical decision support platform[4][1][2].

Therapeutic areas: OncologyNeurology
Modalities: Device
Industry: Medical Imaging

Partnerships

University of ManchesterHealth Innovation Manchester (ERDF R&I Health Accelerator)

Beyond the preview

Go deeper on Ainostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ainostics.

Explore the full profile